跳转至内容
Merck
所有图片(2)

Key Documents

HTS080M

Sigma-Aldrich

ChemiSCREEN Human NK1 Tachykinin Receptor Membrane Preparation

Human NK1 GPCR membrane preparation for Radioligand binding Assays & GTPγS binding.

登录查看公司和协议定价


About This Item

分類程式碼代碼:
41106514
eCl@ss:
32161000
NACRES:
NA.84

生物源

human

品質等級

重組細胞

expressed in Chem-1 cells

製造商/商標名

ChemiScreen
Chemicon®

技術

ligand binding assay: suitable (GTPγS)
radioligand binding assay (RLBA): suitable

UniProt登錄號

運輸包裝

dry ice

一般說明

Full-length human TACR1 cDNA encoding NK1
The tachykinin peptide family in mammals comprises three peptides, substance P, neurokinin A and neurokinin B, which bind to the tachykinin receptor family of GPCRs, NK1, NK2 and NK3 (Severini et al., 2002). Tachykinins have prominent activity in the GI system, in which they stimulate intestinal contraction and salivation. These effects are mediated by NK1 and NK2, and an antagonist of NK1, aprepitant, is used for treatment of chemotherapy-induced emesis (Rupniak and Kramer, 1999). The NK1 tachykinin receptor is expressed in brain, and is thought to be involved in depression and nociception (Saria, 1999). Although NK1 appears to promote nociception in animal models, the significance of this activity is controversial, as antagonists of NK1 have not proven efficacious in pain relief in humans (Hill, 2000). Chemicon′s NK1 membrane preparations are crude membrane preparations made from our proprietary stable recombinant cell lines to ensure high-level of GPCR surface expression; thus, they are ideal HTS tools for screening of antagonists of NK1 interactions with Substance P. The membrane preparations exhibit a Kd of 0.28-0.4 nM for [125I]-Substance P. With 10 µg/well NK1 Membrane Prep and 0.25 nM [125I]-Substance P, a greater than 5-fold signal-to-background ratio was obtained.

應用

Radioligand binding assay and GTPγS binding.

生化/生理作用

GPCR Class: A
Protein Target: NK1
Target Sub-Family: Tackykinin /neurokinin

品質



Signal:background and specific binding values obtained in a competition binding assay with varying amounts of NK1 membrane prep:
10 µg/well
Signal:Background 7.17
Specific Binding (cpm) 2210


SPECIFICATIONS: 1 unit = 10 µg
Bmax : 0.38 pmol/mg
Kd: 0.34 nM

規格

Inucbation Conditions
Membranes are mixed with radioactive ligand and unlabeled competitor (see Figures 1 and 2 for concentrations tested) in binding buffer in a nonbinding 96-well plate, and incubated for 1-2 h. Prior to filtration, a GF/C 96-well filter plate is coated with 0.33% polyethyleneimine for 30 min, then washed with 50mM HEPES, pH 7.4, 0.5% BSA. Binding reaction is transferred to the filter plate, and washed 3 times (1 mL per well per wash) with Wash Buffer. The plate is dried and counted.
Binding buffer: 50 mM Hepes, pH 7.4, 5 mM MgCl2, 1 mM CaCl2, 0.2% BSA, filtered and stored at 4°C
Radioligand: [125I]-Substance P (Perkin Elmer#:NEX190 )
Wash Buffer: 50 mM Hepes, pH 7.4, 500mM NaCl , 0.1% BSA, filtered and stored at 4°C.
One package contains enough membranes for at least 200 assays (units), where a unit is the amount of membrane that will yield greater than 5-fold signal:background with 125I labeled Substance P at 0.25 nM

外觀

Liquid in packaging buffer: 50 mM Tris pH 7.4, 10% glycerol and 1% BSA no preservatives.
Packaging method: Membranes protein were adjusted to 0.5 mg/ml in 1 mL packaging buffer, rapidly frozen, and stored at -80°C.

儲存和穩定性

Maintain frozen at -70°C for up to 2 years. Do not freeze and thaw.

法律資訊

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

免責聲明

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

儲存類別代碼

10 - Combustible liquids

水污染物質分類(WGK)

WGK 1

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

N M Rupniak et al.
Trends in pharmacological sciences, 20(12), 485-490 (2000-02-12)
The development of small-molecule antagonists of the substance P (SP)-preferring tachykinin NK1 receptor during the past decade represents an important opportunity to exploit these molecules as novel therapeutic agents. On the basis of its anatomical localization and function, SP has
R Hill
Trends in pharmacological sciences, 21(7), 244-246 (2000-06-29)
Tachykinin NK1 receptor antagonists have failed to exhibit efficacy in clinical trials of a variety of clinical pain states. By contrast, in preclinical studies in animals NK1 receptor antagonists have been shown to attenuate nociceptive responses sensitized by inflammation or
Cinzia Severini et al.
Pharmacological reviews, 54(2), 285-322 (2002-05-31)
The tachykinin peptide family certainly represents one of the largest peptide families described in the animal organism. So far, more than 40 tachykinins have been isolated from invertebrate (insects, worms, and molluscs), protochordate, and vertebrate (skin, gastrointestinal tract, peripheral and
A Saria
European journal of pharmacology, 375(1-3), 51-60 (1999-08-12)
After its discovery in 1931, substance P (SP) remained the only mammalian member of the family of tachykinin peptides for several decades. Tachykinins thus refer to peptides sharing the common C-terminal amino acid sequence Phe-X-Gly-Leu-Met x NH2. In recent years

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门